Article info

Download PDFPDF

Extended report
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Authors

  1. Correspondence to Professor Mikkel Østergaard, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Nordre Ringvej 57, Glostrup DK-2600, Denmark; mo{at}dadlnet.dk
View Full Text

Citation

Østergaard M, Jacobsson LTH, Schaufelberger C, et al
MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16

Publication history

  • Received July 25, 2014
  • Revised November 12, 2014
  • Accepted November 15, 2014
  • First published December 15, 2014.
Online issue publication 
May 08, 2015

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.